{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T01:55:12Z","timestamp":1785117312071,"version":"3.55.0"},"reference-count":72,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P30CA033572"],"award-info":[{"award-number":["P30CA033572"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The complexity of cancer care requires integrated and continuous support to deliver appropriate care. An expert network with complementary expertise and the capability of multidisciplinary care is an integral part of contemporary oncology care. Appropriate infrastructure is necessary to empower this network to deliver personalized precision care to their patients. Providing decision support as cancer care becomes exponentially more complex with new diagnostic and therapeutic choices remains challenging. City of Hope has developed a Pyramidal Decision Support Framework to address these challenges, which were exacerbated by the COVID pandemic, health plan restrictions, and growing geographic site diversity. Optimizing efficient and targeted decision support backed by multidisciplinary cancer expertise can improve individual patient treatment plans to achieve improved care and survival wherever patients are treated.<\/jats:p>","DOI":"10.3390\/jcm11226738","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T02:32:16Z","timestamp":1668479536000},"page":"6738","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pyramidal Decision Support Framework Leverages Subspecialty Expertise across Enterprise to Achieve Superior Cancer Outcomes and Personalized, Precision Care Plans"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3897-4276","authenticated-orcid":false,"given":"Linda D.","family":"Bosserman","sequence":"first","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope, Irwindale, CA 91706, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isa","family":"Mambetsariev","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2668-3415","authenticated-orcid":false,"given":"Colton","family":"Ladbury","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, City of Hope, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsaneh","family":"Barzi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope, Irwindale, CA 91706, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deron","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Clinical Informatics, City of Hope, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Morse","sequence":"additional","affiliation":[{"name":"Department of Quality, Risk and Regulatory Management, City of Hope, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Deaville","sequence":"additional","affiliation":[{"name":"Department of Enterprise Business Intelligence, City of Hope, Irwindale, CA 91706, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wade","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope, Newport Beach, CA 92660, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapnil","family":"Rajurkar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope, Upland, CA 91784, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amartej","family":"Merla","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope, Antelope Valley, CA 93534, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Hajjar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope, Mission Hills, CA 91345, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4684-8114","authenticated-orcid":false,"given":"Jeremy","family":"Fricke","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Trisal","sequence":"additional","affiliation":[{"name":"Department of Medicine, City of Hope, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9643-7626","authenticated-orcid":false,"given":"Ravi","family":"Salgia","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"American Society of Clinical Oncology (2016). The State of Cancer Care in America, 2016: A Report by the American Society of Clinical Oncology. J. Oncol. Pract., 12, 339\u2013383.","DOI":"10.1200\/JOP.2015.010462"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e412","DOI":"10.1200\/JOP.18.00149","article-title":"The State of Oncology Practice in America, 2018: Results of the ASCO Practice Census Survey","volume":"14","author":"Kirkwood","year":"2018","journal-title":"J. Oncol. Pract."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JOP.18.00658","article-title":"Benefits and Challenges of Growing Oncology Networks in the United States","volume":"14","author":"Bosserman","year":"2018","journal-title":"J. Oncol. Pract."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Rajurkar, S., Mambetsariev, I., Pharaon, R., Leach, B., Tan, T., Kulkarni, P., and Salgia, R. (2020). Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies. J. Clin. Med., 9.","DOI":"10.3390\/jcm9061870"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Bosserman, L.D., Cianfrocca, M., Yuh, B., Yeon, C., Chen, H., Sentovich, S., Polverini, A., Zachariah, F., Deaville, D., and Lee, A.B. (2021). Integrating Academic and Community Cancer Care and Research through Multidisciplinary Oncology Pathways for Value-Based Care: A Review and the City of Hope Experience. J. Clin. Med., 10.","DOI":"10.3390\/jcm10020188"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/cncr.27935","article-title":"Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer","volume":"119","author":"Boland","year":"2013","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1477-2574.2012.00496.x","article-title":"Failure to comply with NCCN guidelines for the management of pancreatic cancer compromises outcomes","volume":"14","author":"Visser","year":"2012","journal-title":"HPB"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/EDBK_174909","article-title":"The Oncology Care Model: Perspectives From the Centers for Medicare & Medicaid Services and Participating Oncology Practices in Academia and the Community","volume":"37","author":"Kline","year":"2017","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e13800","DOI":"10.2196\/13800","article-title":"Personalizing Value in Cancer Care: The Case for Incorporating Patient Preferences Into Routine Clinical Decision Making","volume":"11","author":"Seidman","year":"2019","journal-title":"J. Particip. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Pfohl, U., Pflaume, A., Regenbrecht, M., Finkler, S., Graf Adelmann, Q., Reinhard, C., Regenbrecht, C.R.A., and Wedeken, L. (2021). Precision Oncology Beyond Genomics: The Future Is Here-It Is Just Not Evenly Distributed. Cells, 10.","DOI":"10.3390\/cells10040928"},{"key":"ref_11","first-page":"e461","article-title":"Tumor boards: Optimizing the structure and improving efficiency of multidisciplinary management of patients with cancer worldwide","volume":"34","author":"Keating","year":"2014","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1634\/theoncologist.2016-0195","article-title":"Key Lessons Learned from Moffitt\u2019s Molecular Tumor Board: The Clinical Genomics Action Committee Experience","volume":"22","author":"Knepper","year":"2017","journal-title":"Oncologist"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1200\/JOP.2015.009134","article-title":"American Society of Clinical Oncology Policy Statement on Clinical Pathways in Oncology","volume":"12","author":"Zon","year":"2016","journal-title":"J. Oncol. Pract."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1200\/JOP.2016.019836","article-title":"American Society of Clinical Oncology Criteria for High-Quality Clinical Pathways in Oncology","volume":"13","author":"Zon","year":"2017","journal-title":"J. Oncol. Pract."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e823","DOI":"10.1200\/JOP.18.00419","article-title":"Measuring the Impact of Academic Cancer Network Development on Clinical Integration, Quality of Care, and Patient Satisfaction","volume":"14","author":"Chiang","year":"2018","journal-title":"J. Oncol. Pract."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1200\/JOP.091058","article-title":"Cost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting","volume":"6","author":"Neubauer","year":"2010","journal-title":"J. Oncol. Pract."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"52s","DOI":"10.1200\/JOP.2011.000318","article-title":"Pathways, outcomes, and costs in colon cancer: Retrospective evaluations in two distinct databases","volume":"7","author":"Hoverman","year":"2011","journal-title":"J. Oncol. Pract."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e12012","DOI":"10.1200\/JCO.2019.37.15_suppl.e12012","article-title":"Use of treatment pathways reduce cost and decrease ED utilization and unplanned hospital admissions in patients (pts) with stage II breast cancer","volume":"37","author":"Weese","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1200\/JOP.2017.021741","article-title":"Cost and Survival Analysis Before and After Implementation of Dana-Farber Clinical Pathways for Patients With Stage IV Non-Small-Cell Lung Cancer","volume":"13","author":"Jackman","year":"2017","journal-title":"J. Oncol. Pract."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1200\/JOP.2014.001488","article-title":"Changing physician incentives for affordable, quality cancer care: Results of an episode payment model","volume":"10","author":"Newcomer","year":"2014","journal-title":"J. Oncol. Pract."},{"key":"ref_21","first-page":"28","article-title":"Anthem\u2019s Clinical Pathways Demonstrate Value: The Payer Perspective","volume":"8","author":"Doyle","year":"2015","journal-title":"Am. Health Drug Benefits"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6553","DOI":"10.1200\/jco.2013.31.15_suppl.6553","article-title":"Validation of observed savings from an oncology clinical pathways program","volume":"31","author":"Scott","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_23","unstructured":"City of Hope (2022, September 13). How Innovations in Multiple Myeloma Care Result in Superior National Survival Outcomes. Available online: https:\/\/www.cityofhope.org\/physician-news\/myeloma-innovations-result-in-superior-survival-outcomes."},{"key":"ref_24","unstructured":"City of Hope (2022, September 13). Lung Cancer Survival Rates Exceed National Averages*. Available online: https:\/\/www.cityofhope.org\/patients\/outcomes\/best-lung-cancer-survival-results-in-southern-california."},{"key":"ref_25","unstructured":"City of Hope (2022, September 13). Breast Cancer Survival Rates at City of Hope Exceed National Averages. Available online: https:\/\/www.cityofhope.org\/physician-news\/coh-breast-cancer-survival-rates-exceed-national-averages."},{"key":"ref_26","unstructured":"City of Hope (2022, September 13). City of Hope Prostate Cancer Outcome Summary. Available online: https:\/\/www.cityofhope.org\/sites\/www\/files\/2022-05\/prostate-outcomes-report-feb2022.pdf."},{"key":"ref_27","unstructured":"City of Hope (2022, September 13). City of Hope Colorectal Cancer Outcome Summary. Available online: https:\/\/www.cityofhope.org\/sites\/www\/files\/2022-05\/colorectal-outcome-summary.pdf."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1093\/jnci\/djz245","article-title":"The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design","volume":"112","author":"Flaherty","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"8098","DOI":"10.1200\/jco.2014.32.15_suppl.8098","article-title":"Effect of reflex testing by pathologists on molecular testing rates in lung cancer patients: Experience from a community-based academic center","volume":"32","author":"Inal","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.cllc.2017.04.004","article-title":"Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities","volume":"18","author":"Gutierrez","year":"2017","journal-title":"Clin. Lung Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1200\/JCO.2019.37.15_suppl.1585","article-title":"Genomic testing and treatment landscape in patients with advanced non-small cell lung cancer (aNSCLC) using real-world data from community oncology practices","volume":"37","author":"Gierman","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2018.9824","article-title":"Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting","volume":"320","author":"Presley","year":"2018","journal-title":"JAMA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00159","article-title":"ALK Testing Trends and Patterns Among Community Practices in the United States","volume":"2","author":"Illei","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"S249","DOI":"10.1016\/j.jtho.2016.09.007","article-title":"ORAL01.02: Biopsies in Initial Diagnosis of Non\u2013Small Cell Lung Cancer in US Community Oncology Practices: Implications for First-Line Immunotherapy: Topic: Medical Oncology","volume":"11","author":"Hussein","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"49","DOI":"10.25270\/jcp.2018.02.00001","article-title":"Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non-Small Cell Lung Cancer Treatment Setting","volume":"4","author":"Mason","year":"2018","journal-title":"J. Clin. Pathw."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1634\/theoncologist.2017-0353","article-title":"Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval","volume":"23","author":"Khozin","year":"2018","journal-title":"Oncologist"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.cllc.2018.02.002","article-title":"Treatment Patterns and Clinical Outcomes Among Metastatic Non\u2013Small-Cell Lung Cancer Patients Treated in the Community Practice Setting","volume":"19","author":"Nadler","year":"2018","journal-title":"Clin. Lung Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"971","DOI":"10.4236\/jct.2019.1012083","article-title":"Biomarker Testing Rates in Patients with Advanced Non-Small Cell Lung Cancer Treated in the Community","volume":"10","author":"Nadler","year":"2019","journal-title":"J. Cancer Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"10529","DOI":"10.1200\/JCO.2021.39.15_suppl.10529","article-title":"Genetic counseling and testing rates among community cancer programs for patients with breast cancer following site-directed quality improvement","volume":"39","author":"Boehmer","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1200\/JCO.18.01854","article-title":"Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients","volume":"37","author":"Kurian","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1200\/JCO.2017.74.5034","article-title":"Cost Effectiveness of Gene Expression Profile Testing in Community Practice","volume":"36","author":"Chandler","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1200\/JOP.18.00661","article-title":"Implementing Precision Medicine in Community-Based Oncology Programs: Three Models","volume":"15","author":"Levit","year":"2019","journal-title":"J. Oncol. Pract."},{"key":"ref_43","unstructured":"Patel, K., Clinton, N., Mukhi, H., and Patel, M. (2022, September 07). The Role of In-Office Next Generation Sequencing to Advance Precision Medicine in Community Oncology. Available online: https:\/\/www.targetedonc.com\/view\/the-role-of-in-office-next-generation-sequencing-to-advance-precision-medicine-in-community-oncology."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"pkab020","DOI":"10.1093\/jncics\/pkab020","article-title":"DeImplementing Ineffective and Low-Value Clinical Practices: Research and Practice Opportunities in Community Oncology Settings","volume":"5","author":"Norton","year":"2021","journal-title":"JNCI Cancer Spectrum."},{"key":"ref_45","first-page":"87","article-title":"Identifying obstacles to optimal integration of cancer immunotherapies in the community setting","volume":"37","author":"Shivakumar","year":"2019","journal-title":"J. Oncol. Pract."},{"key":"ref_46","first-page":"50","article-title":"Germline testing for prostate cancer: Community urology perspective","volume":"26","author":"Concepcion","year":"2019","journal-title":"Can. J. Urol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e2019452","DOI":"10.1001\/jamanetworkopen.2020.19452","article-title":"Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer","volume":"3","author":"Lincoln","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/s41391-021-00469-3","article-title":"Disparities in germline testing among racial minorities with prostate cancer","volume":"25","author":"Weise","year":"2022","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/OP.21.00297","article-title":"Calling Attention to the Role of Race-Driven Societal Determinants of Health on Aggressive Tumor Biology: A Focus on Black Americans","volume":"18","author":"Ashing","year":"2022","journal-title":"JCO Oncol. Pract."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"9005","DOI":"10.1200\/JCO.2021.39.15_suppl.9005","article-title":"Racial disparities in biomarker testing and clinical trial enrollment in non-small cell lung cancer (NSCLC)","volume":"39","author":"Bruno","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e2115675","DOI":"10.1001\/jamanetworkopen.2021.15675","article-title":"Trends in Patient Volume by Hospital Type and the Association of These Trends With Time to Cancer Treatment Initiation","volume":"4","author":"Frosch","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3747\/co.25.4088","article-title":"Oncology communities of practice: Insights from a qualitative analysis","volume":"25","author":"Fingrut","year":"2018","journal-title":"Curr. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JOP.2014.001424","article-title":"The Changing Face of Research in Community Practice","volume":"10","author":"Zon","year":"2014","journal-title":"J. Oncol. Pract."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Freytag, M., Herrlinger, U., Hauser, S., Bauernfeind, F.G., Gonzalez-Carmona, M.A., Landsberg, J., Buermann, J., Vatter, H., Holderried, T., and Send, T. (2020). Higher number of multidisciplinary tumor board meetings per case leads to improved clinical outcome. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-06809-1"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1200\/JCO.2000.18.11.2327","article-title":"Hospital and physician volume or specialization and outcomes in cancer treatment: Importance in quality of cancer care","volume":"18","author":"Hillner","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1177\/1077558709335536","article-title":"Influence of NCI cancer center attendance on mortality in lung, breast, colorectal, and prostate cancer patients","volume":"66","author":"Onega","year":"2009","journal-title":"Med. Care Res. Rev."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"29877","DOI":"10.18632\/oncotarget.25643","article-title":"Heuristic value-based framework for lung cancer decision-making","volume":"9","author":"Mambetsariev","year":"2018","journal-title":"Oncotarget"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e1427","DOI":"10.1002\/onco.13807","article-title":"Temporal Trends in Inpatient Oncology Census Before and During the COVID-19 Pandemic and Rates of Nosocomial COVID-19 Among Patients with Cancer at a Large Academic Center","volume":"26","author":"Zubiri","year":"2021","journal-title":"Oncologist"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1200\/JCO.2020.38.29_suppl.51","article-title":"Effects of COVID-19 on an academic breast oncology center in New York City","volume":"38","author":"Prigoff","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"15792","DOI":"10.18632\/oncotarget.24353","article-title":"Value-based genomics","volume":"9","author":"Gong","year":"2018","journal-title":"Oncotarget"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1001\/jamaoncol.2021.1512","article-title":"The Oncology Care Model at 5 Years-Value-Based Payment in the Precision Medicine Era","volume":"7","author":"Mullangi","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Olver, I., Carey, M., Bryant, J., Boyes, A., Evans, T., and Sanson-Fisher, R. (2020). Second opinions in medical oncology. BMC Palliat. Care, 19.","DOI":"10.1186\/s12904-020-00619-9"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/jamiaopen\/ooz045","article-title":"A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients","volume":"2","author":"Pishvaian","year":"2019","journal-title":"JAMIA Open"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1200\/JOP.2013.000882","article-title":"Development of a virtual multidisciplinary lung cancer tumor board in a community setting","volume":"9","author":"Stevenson","year":"2013","journal-title":"J. Oncol. Pract."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1002\/cncr.22266","article-title":"Changes in surgical management resulting from case review at a breast cancer multidisciplinary tumor board","volume":"107","author":"Newman","year":"2006","journal-title":"Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/jnci\/djs502","article-title":"Tumor boards and the quality of cancer care","volume":"105","author":"Keating","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1046\/j.1365-2923.2001.00919.x","article-title":"Interdisciplinary education and teamwork: A long and winding road","volume":"35","author":"Hall","year":"2001","journal-title":"Med. Educ."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.ejca.2007.01.025","article-title":"Multidisciplinary cancer conferences: A systematic review and development of practice standards","volume":"43","author":"Wright","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Lesslie, M., and Parikh, J.R. (2017). Implementing a Multidisciplinary Tumor Board in the Community Practice Setting. Diagnostics, 7.","DOI":"10.3390\/diagnostics7040055"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.acra.2016.09.006","article-title":"Multidisciplinary Tumor Boards: An Opportunity for Radiologists to Demonstrate Value","volume":"24","author":"Lesslie","year":"2017","journal-title":"Acad. Radiol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s41030-021-00163-8","article-title":"Virtual Multidisciplinary Tumor Boards: A Narrative Review Focused on Lung Cancer","volume":"7","author":"Gebbia","year":"2021","journal-title":"Pulm. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/jnci\/djz234","article-title":"Evolution of Cancer Care Delivery Research in the NCI Community Oncology Research Program","volume":"112","author":"Geiger","year":"2020","journal-title":"J. Natl. Cancer Inst."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/22\/6738\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:18:01Z","timestamp":1760145481000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/22\/6738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,14]]},"references-count":72,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["jcm11226738"],"URL":"https:\/\/doi.org\/10.3390\/jcm11226738","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,14]]}}}